MOVA: new method for evaluating the pathogenicity of missense variants using AlphaFold2

Niigata, Japan – The Department of Neurology at Niigata University has developed a new in silico method for evaluating the pathogenicity of missense variants using AlphaFold2 (MOVA). Rare variants in the causative gene of ALS are present in 10-30% of sporadic ALS cases, which highlights the need for accurate and efficient pathogenicity prediction methods. To predict the pathogenicity of the variants, in silico analysis methods are commonly used. In some ALS causal genes, the mutations are concentrated in specific regions, and the accuracy of pathogenicity prediction can be improved by considering the positional information of the variants. However, existing methods have not well considered information on the position of variants in the protein’s structure. MOVA was developed to address this issue and focuses on using positional information in the 3D structure to evaluate the pathogenicity of missense variants. The use of machine learning method, random forest, in the development of MOVA has also shown promising results. “The comparison of MOVA with existing in silico analysis methods, such as PolyPhen-2, CADD, REVEL, EVE, and AlphScore, demonstrates its potential in pathogenicity prediction. Combining MOVA with existing methods, such as REVEL and CADD, further improves performance beyond existing pathogenicity prediction methods alone. Moreover, MOVA also showed superior pathogenicity discrimination of hotspot mutations in the TARDBP and FUS genes. This highlights the importance of considering the positional information of variants in protein structures for improved pathogenicity prediction.”  explain Dr. Hatano and Dr. Ishihara. The results of the study were published in the online edition of the journal BMC Bioinformatics on 2023.

Credit: The image may only be used with appropriate caption or credit.